Boston Partners
KALA icon

Boston Partners’s KALA BIO KALA Stock Holding History

Boston Partners’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-56
Closed -$516K – 695
2019
Q4 		$516K Buy
56
+6
+12% +$57.9K ﹤0.01% 623
2019
Q3 		$472K Buy
50
+3
+6% +$36.5K ﹤0.01% 624
2019
Q2 		$756K Buy
47
+40
+571% +$662K ﹤0.01% 625
2019
Q1 		$152K Buy
+7
New +$124K ﹤0.01% 675

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $16.1B AUM 40.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners's KALA Position: Q1 2020 in Review

Boston Partners sold out of KALA BIO (KALA) in Q1 2020, closing a stake of 56 shares — an estimated $516K sold.

Boston Partners first reported a position in KALA in Q1 2019 and held it in 4 quarters. The position peaked at $756K in Q2 2019. 83 funds tracked by Wall St. Rank hold KALA as of Q1 2020.

  • Boston Partners reported no remaining KALA BIO position as of Q1 2020 after selling out during the quarter.
  • Boston Partners sold 56 KALA BIO shares in Q1 2020, an estimated $516K.
  • Boston Partners first reported a position in KALA BIO in Q1 2019 and held it in 4 quarters.
  • Boston Partners's KALA BIO position peaked at $756K in Q2 2019.
  • 83 funds tracked by Wall St. Rank held KALA BIO as of Q1 2020.

Based on Boston Partners's 13F filing for Q1 2020, filed 13 May 2020.